Nearly one third of Zimmer Biomet's robots are going to ASCs, according to a Nov. 2 third quarter earnings call.
About 30 percent of the medical device company's robotics are placed in ASCs, and half of all robotic installations are in the U.S., COO Ivan Tornos said in the call.
During the third quarter, Zimmer Biomet doubled down on robotics through a partnership with New York City-based Hospital for Special Surgery. Under the partnership, Zimmer Biomet will focus on developing artificial intelligence tools to provide insights for robot-assisted joint surgery.
Zimmer Biomet is also homing in on ASCs and looking for more ways to spend in that market.
"Number one, we're putting infrastructure in place," CEO Bryan Hanson said, as transcribed by Seeking Alpha. "We've got dedicated commercial teams that focus only on the ASC, and that's important because you've got to have contracting prowess in that space and we've done that over the last couple of years and really getting good traction as a result of it. Additionally, we're making sure that we scale up in the product categories that the ASC is looking for."